Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center

Jaime-Perez Jose C.; Padilla-Medina Jose R.; Salazar-Cavazos Lorena; Fernandez Lucia T.; Gomez-Almaguer David

首页> 外文期刊>Hematological oncology >Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center

【24h】

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center

机译：在60岁左右的患者中治疗弥漫性大B细胞淋巴瘤，无蒽氟胺和毒素肢体：拉丁美洲中心的10年结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hematological oncology》 |2019年第s2期|共4页
作者
Jaime-Perez Jose C.; Padilla-Medina Jose R.; Salazar-Cavazos Lorena; Fernandez Lucia T.; Gomez-Almaguer David;
展开▼
作者单位

Univ Autonoma Nuevo Leon Dr Jose E Gonzalez Univ Hosp Sch Med Internal Med Div Dept Hematol;

Univ Autonoma Nuevo Leon Dr Jose E Gonzalez Univ Hosp Sch Med Internal Med Div Dept Hematol;

Univ Autonoma Nuevo Leon Dr Jose E Gonzalez Univ Hosp Sch Med Internal Med Div Dept Hematol;

Univ Autonoma Nuevo Leon Dr Jose E Gonzalez Univ Hosp Sch Med Internal Med Div Dept Hematol;

Univ Autonoma Nuevo Leon Dr Jose E Gonzalez Univ Hosp Sch Med Internal Med Div Dept Hematol;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center [J] . Jaime-Perez Jose C., Padilla-Medina Jose R., Salazar-Cavazos Lorena, Hematological oncology . 2019,第S2期

机译：在60岁左右的患者中治疗弥漫性大B细胞淋巴瘤，无蒽氟胺和毒素肢体：拉丁美洲中心的10年结果
2. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. [J] . Link BK, Brooks J, Wright K, Leukemia and lymphoma . 2011,第6期

机译：老年人弥漫性大B细胞淋巴瘤：使用或不使用蒽环类药物，利妥昔单抗治疗的扩散和生存率的提高。
3. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. [J] . Natkunam Y, Farinha P, Hsi ED, Journal of Clinical Oncology . 2008,第3期

机译：LMO2蛋白表达可预测以蒽环类为基础的化疗（有或没有利妥昔单抗）治疗的弥漫性大B细胞淋巴瘤患者的生存。
4. Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models [C] . Chin-Chuan Chang, Chien-Hua Chen, Jer-Guang Hsieh, IEEE Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability . 2021

机译：逻辑和神经网络模型弥漫性大B细胞淋巴瘤患者的存活预测
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines [O] . BRIAN K. LINK, JOHN BROOKS, KARA WRIGHT, -1

机译：弥漫性大型B细胞淋巴瘤在老年人中：用Rituximab和生存率的扩散含有蒽环类的生存进展
7. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi [O] . Sergio Storti, Michele Spina, Emanuela Anna Pesce, 2018

机译：Rituximab Plus Bendamustine作为Frillual（> 70年）弥漫性大B细胞非霍奇金淋巴瘤患者的前线治疗患者：II期的Fondazione Italiana Linfomi的多中心研究

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center

著录项

相似文献

相关主题

期刊订阅